BROWSE THROUGH PROJECTS FUNDED BY ODIN

Here you will find an overview of the research projects funded by ODIN since 2020.

You can browse by project themes in the fold-out menu or by project acronyms below.

You are welcome to contact the head of projects if you have any questions about the individual projects or outcomes.

Cardiometabolic Diseases (CMD)

Jørgen Kjems, Head of the oLIVER Project. Photo credit: Lars Kruse

oLIVER - identifying biomarkers for diagnosis and treatment evaluation of non-alcoholic fatty liver disease (NAFLD)

Jørgen Kjems, Professor, AU

Pilot project (2020 - 2023)

Lene Nejsum & Rikke Nørregaard, Heads of the FRIGG Project. Photo credit: Lars Kruse

FRIGG - fresh human kidney tissue: exploring biomarkers and intervention targets in CKD

Lene Niemann Nejsum, and Rikke Nørregaard, Professor, AU

Pilot project (2021 - 2023)

Robert Fenton, Head of the KidDO Project. Photo credit: Lars Kruse

KidDO - open discovery of metabolic targets for therapeutic intervention in kidney disease

Robert Fenton, Professor, AU

Pilot project (2021 - 2023)

Peter Sørensen, Head of the BALDER Project. Photo credit: Lars Kruse

BALDER - bayesian analysis of diabetes for enhanced biomarker and drug target identification

Peter Sørensen, Senior Scientist, AU

Pilot project (2021 - 2023)

ADIPOTECH - engineering adipose tissue organoids for developing novel therapeutics

Zach Gerhart-Hines, Associate Professor, KU

Grant Type 1 project (2025 - 2028)

KIDnEx2 - Kidney inverse drug discovery: Exploring and exploiting the ligandable proteome

Markus Rinschen, Associate Professor, AU

Grant Type 1 project (2025 - 2028)

Cardiovascular Diseases (CVD)

Jacob Fog Bentzon, Head of the THOR Project. Photo credit: Lars Kruse

THOR - targeting smooth muscle cells for atherosclerosis therapy

Jacob Fog Bentzon, Professor, AU

Pilot project (2021 - 2023)

SIF - advancing drug testing assays for atherosclerosis treatment

Lasse Bach Steffensen, Associate Professor, SDU

Grant Type 1 project (2025 - 2028)

Successor to the THOR project

FibroCard - platform for studying and targeting fibrosis in cardiac disease

Bo Hjorth Bentzen, Associate Professor, KU

Grant Type 1 project (2025 - 2028)

Infectious Diseases

IMPACT - improving the pig biomedical model for accelerating translational research in anti-infection drugs and prophylaxes

Thomas Emil Andersen, Professor, SDU

Grant Type 1 project (2025 - 2028)

Diseases of the central nervous system (CNS)

Betina Elfving, Head of the BioPsych project. Photo credit: Lars Kruse

BioPsych - identification of biomarkers in the human psychiatric brain – focusing on non-coding RNAs and sex differences

Betina Elfving, Associate Professor, AU

Pilot project (2021 - 2023)

Marina Romero-Ramos, Head of the IMPAD project. Photo credit: Lars Kruse

IMPAD - Immune-related biomarkers and targets in Parkinson's disease

Marina Romero-Ramos, Professor, AU

Pilot project (2021 - 2023)

MiCO Platform - a human stem cell-based miniaturised controlled organoid (MiCO) platform for investigating neurological disorders

Mark Denham, Associate Professor, AU

Pilot project (2021 - 2023)

T-GATE - tanycyte-based platform for investigating brain uptake of metabolic peptides and drugs

Birger Brodin, Professor, KU

Grant Type 1 project (2025 - 2027)

Other disease areas

Lasse Sommer Kristensen, Head of the BIOMETSCO Project. Photo credit: Lars Kruse

BIOMETSCO - Identification of novel biomarkers and drug targets for the detection and elimination of occult metastases in colon cancer

Lasse Sommer Kristensen, Associate Professor, AU

Pilot project (2021 - 2023)

Hanne Poulsen, Head of the P2P CPP Project. Photo credit: Lars Kruse

P2P CPP - optimization of cell-penetrating peptides to enable therapeutics with intracellular targets

Hanne Poulsen, Associate Professor, AU

Pilot project (2021 - 2023)

Duncan Sutherland, Head of the CELPPLUS Project. Photo credit: Lars Kruse

CELPPLUS - Advanced 2D CELL culture for improved Phenotype assays

Duncan Sutherland, Professor, AU

Pilot project (2022 - 2023)

Our Projects

ABOUT ODIN

We unite bright minds from industry and academia to jointly create need-driven clinical research projects - and pave the way for innovative new treatments and diagnostics. We fund the best project ideas through competitive funding calls. Although companies cannot receive funding, it is free of charge to join.

The platform is sponsored by the Novo Nordisk Foundation with 180 million DKK from 2024-2029.

CONTACT ODIN

You are welcome to contact us if you have questions or comments. Reach out to odin@au.dk or find the Secretariat's direct email addresses under contacts.

Although the platform spans five Danish universities, we're based in Aarhus. Our office is located at Aarhus University, Ny Munkegade 116, Bldg 1535-117.

Revised 14.07.2026

Jerin Lubna